PRINCETON, N.J., September 25, 2022 – Certara, a global leader in biosimulation, today announced it will host the second annual New Horizons in Pediatric Drug Development Symposium from October 27-28, 2022. The two-day virtual symposium brings together global thought leaders from academia, industry, patient advocacy organizations and health authorities to discuss the latest innovations in pediatric drug development.
“We are thrilled to announce the return of the New Horizons in Pediatric Drug Development Symposium. In 2021, we had the honor of engaging with more than 1,500 participants and viewers on the unique challenges facing drug developers on therapies for children,” said Patrick F. Smith, Pharm.D., President, Integrated Drug Development of Certara. “This year, we are eager to expand upon the conversation and host leading experts to share ideas and new advancements that may overcome these challenges and accelerate the development of pediatric therapies.”
This year’s agenda features keynote speaker Neil Sebire, M.D., Professor of Pediatric Pathology and Chief Research Information Officer at Great Ormond Street Hospital and inaugural Chief Clinical Data Officer at Health Data Research (HDR) UK. Professor Sebire’s expertise includes paediatric and placental pathology, in addition to optimization of health data and technology for research. At the symposium, he will be discussing the importance and limitations of data science, informatics and artificial intelligence using routine electronic health data for future considerations in pediatric drug development.
Additional topics at this year’s symposium covered by more than 20 speakers and panel members include the challenges and opportunities in the execution of pediatric clinical trials, the impact of Project Optimus on pediatric oncology drug development, and pediatric treatments in infectious disease and rare diseases.
To register for the virtual symposium please visit https://www.newhorizonpdd.org/.
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.
Jieun W. Choe